Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.
Gastric Adenocarcinoma
DRUG: Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
R0 resection rate, Proportion of patients who achieved R0 resection, within 4 weeks following the operation
Progression free survival (PFS), the time from registration to the date of disease progression or death resulting from any cause., 5 years|overall survival (OS), the time from registration to the date of death resulting from any cause or the last follow-up visit., 5 years|Adverse Events(AEs), AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0., until 28 days after the last study drug administration
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.